2026 Q1 -tulosraportti
Vain PDF
86 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·14 t sittenStock status. Medcanonestop was sold out at one pharmacy yesterday, today they are sold out at 3 pharmacies. Green Medical is sold out at 2 pharmacies Canngo is sold out at 2 pharmacies Flowzz was sold out at 1 pharmacy yesterday, today they are sold out at 2 pharmacies. Everything else is status Quo Good weekend to all.- ·2 päivää sittenNew update on stock status. I just want to check if the different pharmacies have the oil in stock again. Last time it was sold out, it only took 2 hours, and then it was back in stock. This evening I have been able to ascertain that Weed.de is sold out at 3 pharmacies. I have double-checked that they have had 7 pharmacies, and I have counted many times that only 4 have the oil in stock. On July 20th, I wrote that they had gone from 3 to 7 pharmacies. Tell me, am I the only one who can see that Weeco Astrum 10/10 is being torn off the shelves in Germany???????? It has been sold out so many times now that I have lost track of the number of times. If the pharmacies that are sold out today do not have the oil in stock again tomorrow, we must expect. Delivery problems have arisen due to bottlenecks. I have been able to ascertain that Weeco Pharma has a warehouse in Düsseldorf, as they can rush-deliver the oil in 2 hours, and they also have a good network, since they have been able to deliver the oil in less than 24 hours the other times it has been sold out. I have to repeat myself. It is insane, and worrying, that there is total silence from Stenocares' management.That's an important point you're making. Firstly, Stenocare has no expenses in Germany regarding the sale of the oil; they have outsourced this to Weeco Pharma. Secondly. It doesn't matter if they have expenses or how much sales they have in Germany, as they should have issued the first company announcement because they started selling Weeco Astrum 10/10 already in Q2. It should have stated approximately: "According to financial law, we must send this announcement to the stock market. The sale of Weeco Astrum 10/10 has started selling in Germany here in Q2. We have stated that there will be no sales, but we have been able to ascertain that there are." The second is if there is an update to the financial statements, this must also be disclosed to the stock market as soon as they become aware of it. It is forbidden by law for them to only disclose it after they have become aware of an upward adjustment; this must be sent out the moment they can see that the financial statements need to be adjusted upwards. (the same applies to downward adjustments) If it turns out that I am right, which I am, then the management will be held accountable for the above negligence, based on the latest updated director's law. This will not affect the stock, because Stenocare makes money regardless of what happens to the management. I understand that my stock portfolios are under discussion, so let's close that once and for all. So it's not an advertisement for the shares I hold in my portfolio. As it is now, I have two stocks where I have invested the most. I own shares in Bioporto because I know they are on the verge of a global breakthrough with their product. The NGAL test. It's a medical stock, and with all medical equipment, it takes time, but it has slowly started; I have the shares I need to have. Stenocare. I started by buying a small portion of shares in Q4 2025. I have been watching this since they started cultivating cannabis flowers in Randers, but chose to enter in 2025. I started on May 13th by being on the heels of Weeco Pharma, and could see how their campaign for Weeco Astrum 10/10 succeeded, As soon as I, I was able to ascertain, and have shared with you here on Nordnet social, that they actually started selling the oil already in Q2, I began selling all other shares except Bioporto, even those at a loss, to buy Stenocare shares. All the new money I have been able to find, which has no deadline, I have used to buy Stenocare shares. I have 1 Hexicon share, purely out of laziness; it's easier to keep an eye on a stock when you own at least 1 share. Can you now understand how serious it is that PJ and TS have not informed the stock market, according to current legislation? Stock trading has almost come to a standstill, and that's because I have shared everything that has happened with Weeco Astrum 10/10 in Germany with you, and all of you and I, who have bought up and saved in our portfolio, have done so because we can see with our own eyes that there ARE sales in Germany. But they refuse to tell the stock market, and if PJ and TS had fulfilled their disclosure obligation, as required by law, this announcement would likely affect the stock price, and it would see a natural increase as management confirms it via a company announcement. We can see that there are many sales in Germany. It has nothing to do with my portfolio, but everything to do with management's behavior.
- ·2 päivää sitten · MuokattuNew Stock update Weeco Astrum 10/10 is selling very fast. Medcanonestop, Sold out at one pharmacy Privatrezept.net. Sold out at one pharmacy Flowzz is sold out at one pharmacy I will keep an eye on whether the oil comes back in stock, and if it goes as fast as last time, it took less than 24 hours. CannaNu: The price of Weeco Astrum10/10 has increased from 4.45€ to 5.02€ per ml. When the price of Weeco Astrum 10/10 has increased, it means there is high demand for the oil. This is really good news for Stenocare's revenues in Q3. Explanation: The people who are not insured in the two health insurance funds that provide 100% reimbursement pay out of their own pocket 5.02€ per ml. Those who are insured get it for free, as it has always been. This is how stock management works in German pharmacies. There is strict legislation in Germany on how stock levels must and should be. Every year, they must report to the authorities what they have in stock, see link. As you can see, it is very time-consuming, so pharmacies will not keep medicine in stock if there is no further sale. To avoid these time-consuming reports, pharmacies will only stock what sells quickly. If there is no further sale, it is an order item but should they have something in stock that for some reason does not sell quickly, they will lower the price completely to get rid of the medicine (to avoid the report). If there is so much flow in the stock that the pharmacist estimates they can sell it before they have to report the inventory, then it is a stock item. The price will be moderate. If the price increases, as it has with Weeco Astrum10/10, it means that people are willing to pay more for the product to get hold of it. I am happy to answer clarifying questions about the above (if I can) https://www.bfarm.de/DE/Bundesopiumstelle/Medizinisches-Cannabis/Meldungen/_node.html
- ·27.7.Just before the German politicians went on summer holiday, they approved a law stating that flower medicine should have its subsidy removed from January 1, 2027. There was vociferous lobbying from the companies that stand to lose money, in an attempt to prevent the subsidy from being removed. See previous post. Now, articles are starting to appear about a worrying number of people being hospitalized with serious side effects because there is too much THC, in relation to CBD. We have known this since the 1980s: that the ratio between THC and CBD must be 1:1, because CBD protects against THC's side effects. There may be more CBD in it, but never more THC For the sake of clarity, Weeco Astrum 10-10 has equal parts THC and CBD and is standardized. It is precisely these two properties that have made doctors willing to prescribe the oil. In addition to the other benefits. This one is from July 2026. We must expect that they will not succeed in preventing the subsidy from being removed. https://www.apotheke-adhoc.de/rubriken/detail/medizinisches-cannabis/cannabis-mehr-klinikeinweisungen-wegen-plattform-angeboten/#Now, it's not me who makes money producing these oils, and I haven't really intended to spend energy convincing you of anything at all. You go ahead and hold them accountable for putting more THC in, when there is evidence that CBD protects against the serious side effects. As I write, this has been known since the 1980s. Incidentally, this is also what doctors have persistently protested against, and they did so when Exilby was approved, there is so much THC in it that lawyers are investigating whether there is corruption involved. Good luck holding them accountable for putting more THC in, compared to CBD.
·24.7.astrum 10-10 in germany. Much has been written about Steno supposedly holding back a potential upward revision and that they should even be reported to the financial supervisory authority etc... I think it's time for some realism. Steno has NOT guided on revenue in 2026 and where the revenue should come from! It has been indicated that after the merger of the 2 companies, revenue from 2025 totals 13 Mdkk Furthermore, nothing has been announced about EBITA from 2026... which is much more important than revenue when the cash register is almost empty !!! After Q1 of 2.7 Mdkk, one is already below what was indicated! The average price of Astrum in germany is 600,- dkk and a 30 ml bottle lasts on average 2 months depending on the doctor's dosage. Since the model involves profit sharing with weeco (when it leaves the pharmacy), we can set Steno's share high at 200,- dkk So even with 1000 new patients in germany (if that were to be the case in Q2), there is NOTHING to blame Steno's management for as it has NO influence on the Q2 report .....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
86 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·14 t sittenStock status. Medcanonestop was sold out at one pharmacy yesterday, today they are sold out at 3 pharmacies. Green Medical is sold out at 2 pharmacies Canngo is sold out at 2 pharmacies Flowzz was sold out at 1 pharmacy yesterday, today they are sold out at 2 pharmacies. Everything else is status Quo Good weekend to all.
- ·2 päivää sittenNew update on stock status. I just want to check if the different pharmacies have the oil in stock again. Last time it was sold out, it only took 2 hours, and then it was back in stock. This evening I have been able to ascertain that Weed.de is sold out at 3 pharmacies. I have double-checked that they have had 7 pharmacies, and I have counted many times that only 4 have the oil in stock. On July 20th, I wrote that they had gone from 3 to 7 pharmacies. Tell me, am I the only one who can see that Weeco Astrum 10/10 is being torn off the shelves in Germany???????? It has been sold out so many times now that I have lost track of the number of times. If the pharmacies that are sold out today do not have the oil in stock again tomorrow, we must expect. Delivery problems have arisen due to bottlenecks. I have been able to ascertain that Weeco Pharma has a warehouse in Düsseldorf, as they can rush-deliver the oil in 2 hours, and they also have a good network, since they have been able to deliver the oil in less than 24 hours the other times it has been sold out. I have to repeat myself. It is insane, and worrying, that there is total silence from Stenocares' management.That's an important point you're making. Firstly, Stenocare has no expenses in Germany regarding the sale of the oil; they have outsourced this to Weeco Pharma. Secondly. It doesn't matter if they have expenses or how much sales they have in Germany, as they should have issued the first company announcement because they started selling Weeco Astrum 10/10 already in Q2. It should have stated approximately: "According to financial law, we must send this announcement to the stock market. The sale of Weeco Astrum 10/10 has started selling in Germany here in Q2. We have stated that there will be no sales, but we have been able to ascertain that there are." The second is if there is an update to the financial statements, this must also be disclosed to the stock market as soon as they become aware of it. It is forbidden by law for them to only disclose it after they have become aware of an upward adjustment; this must be sent out the moment they can see that the financial statements need to be adjusted upwards. (the same applies to downward adjustments) If it turns out that I am right, which I am, then the management will be held accountable for the above negligence, based on the latest updated director's law. This will not affect the stock, because Stenocare makes money regardless of what happens to the management. I understand that my stock portfolios are under discussion, so let's close that once and for all. So it's not an advertisement for the shares I hold in my portfolio. As it is now, I have two stocks where I have invested the most. I own shares in Bioporto because I know they are on the verge of a global breakthrough with their product. The NGAL test. It's a medical stock, and with all medical equipment, it takes time, but it has slowly started; I have the shares I need to have. Stenocare. I started by buying a small portion of shares in Q4 2025. I have been watching this since they started cultivating cannabis flowers in Randers, but chose to enter in 2025. I started on May 13th by being on the heels of Weeco Pharma, and could see how their campaign for Weeco Astrum 10/10 succeeded, As soon as I, I was able to ascertain, and have shared with you here on Nordnet social, that they actually started selling the oil already in Q2, I began selling all other shares except Bioporto, even those at a loss, to buy Stenocare shares. All the new money I have been able to find, which has no deadline, I have used to buy Stenocare shares. I have 1 Hexicon share, purely out of laziness; it's easier to keep an eye on a stock when you own at least 1 share. Can you now understand how serious it is that PJ and TS have not informed the stock market, according to current legislation? Stock trading has almost come to a standstill, and that's because I have shared everything that has happened with Weeco Astrum 10/10 in Germany with you, and all of you and I, who have bought up and saved in our portfolio, have done so because we can see with our own eyes that there ARE sales in Germany. But they refuse to tell the stock market, and if PJ and TS had fulfilled their disclosure obligation, as required by law, this announcement would likely affect the stock price, and it would see a natural increase as management confirms it via a company announcement. We can see that there are many sales in Germany. It has nothing to do with my portfolio, but everything to do with management's behavior.
- ·2 päivää sitten · MuokattuNew Stock update Weeco Astrum 10/10 is selling very fast. Medcanonestop, Sold out at one pharmacy Privatrezept.net. Sold out at one pharmacy Flowzz is sold out at one pharmacy I will keep an eye on whether the oil comes back in stock, and if it goes as fast as last time, it took less than 24 hours. CannaNu: The price of Weeco Astrum10/10 has increased from 4.45€ to 5.02€ per ml. When the price of Weeco Astrum 10/10 has increased, it means there is high demand for the oil. This is really good news for Stenocare's revenues in Q3. Explanation: The people who are not insured in the two health insurance funds that provide 100% reimbursement pay out of their own pocket 5.02€ per ml. Those who are insured get it for free, as it has always been. This is how stock management works in German pharmacies. There is strict legislation in Germany on how stock levels must and should be. Every year, they must report to the authorities what they have in stock, see link. As you can see, it is very time-consuming, so pharmacies will not keep medicine in stock if there is no further sale. To avoid these time-consuming reports, pharmacies will only stock what sells quickly. If there is no further sale, it is an order item but should they have something in stock that for some reason does not sell quickly, they will lower the price completely to get rid of the medicine (to avoid the report). If there is so much flow in the stock that the pharmacist estimates they can sell it before they have to report the inventory, then it is a stock item. The price will be moderate. If the price increases, as it has with Weeco Astrum10/10, it means that people are willing to pay more for the product to get hold of it. I am happy to answer clarifying questions about the above (if I can) https://www.bfarm.de/DE/Bundesopiumstelle/Medizinisches-Cannabis/Meldungen/_node.html
- ·27.7.Just before the German politicians went on summer holiday, they approved a law stating that flower medicine should have its subsidy removed from January 1, 2027. There was vociferous lobbying from the companies that stand to lose money, in an attempt to prevent the subsidy from being removed. See previous post. Now, articles are starting to appear about a worrying number of people being hospitalized with serious side effects because there is too much THC, in relation to CBD. We have known this since the 1980s: that the ratio between THC and CBD must be 1:1, because CBD protects against THC's side effects. There may be more CBD in it, but never more THC For the sake of clarity, Weeco Astrum 10-10 has equal parts THC and CBD and is standardized. It is precisely these two properties that have made doctors willing to prescribe the oil. In addition to the other benefits. This one is from July 2026. We must expect that they will not succeed in preventing the subsidy from being removed. https://www.apotheke-adhoc.de/rubriken/detail/medizinisches-cannabis/cannabis-mehr-klinikeinweisungen-wegen-plattform-angeboten/#Now, it's not me who makes money producing these oils, and I haven't really intended to spend energy convincing you of anything at all. You go ahead and hold them accountable for putting more THC in, when there is evidence that CBD protects against the serious side effects. As I write, this has been known since the 1980s. Incidentally, this is also what doctors have persistently protested against, and they did so when Exilby was approved, there is so much THC in it that lawyers are investigating whether there is corruption involved. Good luck holding them accountable for putting more THC in, compared to CBD.
- ·24.7.astrum 10-10 in germany. Much has been written about Steno supposedly holding back a potential upward revision and that they should even be reported to the financial supervisory authority etc... I think it's time for some realism. Steno has NOT guided on revenue in 2026 and where the revenue should come from! It has been indicated that after the merger of the 2 companies, revenue from 2025 totals 13 Mdkk Furthermore, nothing has been announced about EBITA from 2026... which is much more important than revenue when the cash register is almost empty !!! After Q1 of 2.7 Mdkk, one is already below what was indicated! The average price of Astrum in germany is 600,- dkk and a 30 ml bottle lasts on average 2 months depending on the doctor's dosage. Since the model involves profit sharing with weeco (when it leaves the pharmacy), we can set Steno's share high at 200,- dkk So even with 1000 new patients in germany (if that were to be the case in Q2), there is NOTHING to blame Steno's management for as it has NO influence on the Q2 report .....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
86 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·14 t sittenStock status. Medcanonestop was sold out at one pharmacy yesterday, today they are sold out at 3 pharmacies. Green Medical is sold out at 2 pharmacies Canngo is sold out at 2 pharmacies Flowzz was sold out at 1 pharmacy yesterday, today they are sold out at 2 pharmacies. Everything else is status Quo Good weekend to all.
- ·2 päivää sittenNew update on stock status. I just want to check if the different pharmacies have the oil in stock again. Last time it was sold out, it only took 2 hours, and then it was back in stock. This evening I have been able to ascertain that Weed.de is sold out at 3 pharmacies. I have double-checked that they have had 7 pharmacies, and I have counted many times that only 4 have the oil in stock. On July 20th, I wrote that they had gone from 3 to 7 pharmacies. Tell me, am I the only one who can see that Weeco Astrum 10/10 is being torn off the shelves in Germany???????? It has been sold out so many times now that I have lost track of the number of times. If the pharmacies that are sold out today do not have the oil in stock again tomorrow, we must expect. Delivery problems have arisen due to bottlenecks. I have been able to ascertain that Weeco Pharma has a warehouse in Düsseldorf, as they can rush-deliver the oil in 2 hours, and they also have a good network, since they have been able to deliver the oil in less than 24 hours the other times it has been sold out. I have to repeat myself. It is insane, and worrying, that there is total silence from Stenocares' management.That's an important point you're making. Firstly, Stenocare has no expenses in Germany regarding the sale of the oil; they have outsourced this to Weeco Pharma. Secondly. It doesn't matter if they have expenses or how much sales they have in Germany, as they should have issued the first company announcement because they started selling Weeco Astrum 10/10 already in Q2. It should have stated approximately: "According to financial law, we must send this announcement to the stock market. The sale of Weeco Astrum 10/10 has started selling in Germany here in Q2. We have stated that there will be no sales, but we have been able to ascertain that there are." The second is if there is an update to the financial statements, this must also be disclosed to the stock market as soon as they become aware of it. It is forbidden by law for them to only disclose it after they have become aware of an upward adjustment; this must be sent out the moment they can see that the financial statements need to be adjusted upwards. (the same applies to downward adjustments) If it turns out that I am right, which I am, then the management will be held accountable for the above negligence, based on the latest updated director's law. This will not affect the stock, because Stenocare makes money regardless of what happens to the management. I understand that my stock portfolios are under discussion, so let's close that once and for all. So it's not an advertisement for the shares I hold in my portfolio. As it is now, I have two stocks where I have invested the most. I own shares in Bioporto because I know they are on the verge of a global breakthrough with their product. The NGAL test. It's a medical stock, and with all medical equipment, it takes time, but it has slowly started; I have the shares I need to have. Stenocare. I started by buying a small portion of shares in Q4 2025. I have been watching this since they started cultivating cannabis flowers in Randers, but chose to enter in 2025. I started on May 13th by being on the heels of Weeco Pharma, and could see how their campaign for Weeco Astrum 10/10 succeeded, As soon as I, I was able to ascertain, and have shared with you here on Nordnet social, that they actually started selling the oil already in Q2, I began selling all other shares except Bioporto, even those at a loss, to buy Stenocare shares. All the new money I have been able to find, which has no deadline, I have used to buy Stenocare shares. I have 1 Hexicon share, purely out of laziness; it's easier to keep an eye on a stock when you own at least 1 share. Can you now understand how serious it is that PJ and TS have not informed the stock market, according to current legislation? Stock trading has almost come to a standstill, and that's because I have shared everything that has happened with Weeco Astrum 10/10 in Germany with you, and all of you and I, who have bought up and saved in our portfolio, have done so because we can see with our own eyes that there ARE sales in Germany. But they refuse to tell the stock market, and if PJ and TS had fulfilled their disclosure obligation, as required by law, this announcement would likely affect the stock price, and it would see a natural increase as management confirms it via a company announcement. We can see that there are many sales in Germany. It has nothing to do with my portfolio, but everything to do with management's behavior.
- ·2 päivää sitten · MuokattuNew Stock update Weeco Astrum 10/10 is selling very fast. Medcanonestop, Sold out at one pharmacy Privatrezept.net. Sold out at one pharmacy Flowzz is sold out at one pharmacy I will keep an eye on whether the oil comes back in stock, and if it goes as fast as last time, it took less than 24 hours. CannaNu: The price of Weeco Astrum10/10 has increased from 4.45€ to 5.02€ per ml. When the price of Weeco Astrum 10/10 has increased, it means there is high demand for the oil. This is really good news for Stenocare's revenues in Q3. Explanation: The people who are not insured in the two health insurance funds that provide 100% reimbursement pay out of their own pocket 5.02€ per ml. Those who are insured get it for free, as it has always been. This is how stock management works in German pharmacies. There is strict legislation in Germany on how stock levels must and should be. Every year, they must report to the authorities what they have in stock, see link. As you can see, it is very time-consuming, so pharmacies will not keep medicine in stock if there is no further sale. To avoid these time-consuming reports, pharmacies will only stock what sells quickly. If there is no further sale, it is an order item but should they have something in stock that for some reason does not sell quickly, they will lower the price completely to get rid of the medicine (to avoid the report). If there is so much flow in the stock that the pharmacist estimates they can sell it before they have to report the inventory, then it is a stock item. The price will be moderate. If the price increases, as it has with Weeco Astrum10/10, it means that people are willing to pay more for the product to get hold of it. I am happy to answer clarifying questions about the above (if I can) https://www.bfarm.de/DE/Bundesopiumstelle/Medizinisches-Cannabis/Meldungen/_node.html
- ·27.7.Just before the German politicians went on summer holiday, they approved a law stating that flower medicine should have its subsidy removed from January 1, 2027. There was vociferous lobbying from the companies that stand to lose money, in an attempt to prevent the subsidy from being removed. See previous post. Now, articles are starting to appear about a worrying number of people being hospitalized with serious side effects because there is too much THC, in relation to CBD. We have known this since the 1980s: that the ratio between THC and CBD must be 1:1, because CBD protects against THC's side effects. There may be more CBD in it, but never more THC For the sake of clarity, Weeco Astrum 10-10 has equal parts THC and CBD and is standardized. It is precisely these two properties that have made doctors willing to prescribe the oil. In addition to the other benefits. This one is from July 2026. We must expect that they will not succeed in preventing the subsidy from being removed. https://www.apotheke-adhoc.de/rubriken/detail/medizinisches-cannabis/cannabis-mehr-klinikeinweisungen-wegen-plattform-angeboten/#Now, it's not me who makes money producing these oils, and I haven't really intended to spend energy convincing you of anything at all. You go ahead and hold them accountable for putting more THC in, when there is evidence that CBD protects against the serious side effects. As I write, this has been known since the 1980s. Incidentally, this is also what doctors have persistently protested against, and they did so when Exilby was approved, there is so much THC in it that lawyers are investigating whether there is corruption involved. Good luck holding them accountable for putting more THC in, compared to CBD.
- ·24.7.astrum 10-10 in germany. Much has been written about Steno supposedly holding back a potential upward revision and that they should even be reported to the financial supervisory authority etc... I think it's time for some realism. Steno has NOT guided on revenue in 2026 and where the revenue should come from! It has been indicated that after the merger of the 2 companies, revenue from 2025 totals 13 Mdkk Furthermore, nothing has been announced about EBITA from 2026... which is much more important than revenue when the cash register is almost empty !!! After Q1 of 2.7 Mdkk, one is already below what was indicated! The average price of Astrum in germany is 600,- dkk and a 30 ml bottle lasts on average 2 months depending on the doctor's dosage. Since the model involves profit sharing with weeco (when it leaves the pharmacy), we can set Steno's share high at 200,- dkk So even with 1000 new patients in germany (if that were to be the case in Q2), there is NOTHING to blame Steno's management for as it has NO influence on the Q2 report .....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt